License from Synaffix focuses on bispecific ADCs This close collaboration between ABL Bio and Synaffix provides optimal conditions to accelerate research and development of resulting next-generation bioconjugates AMSTERDAM, THE NETHERLANDS, 13 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage platform technology for the development of antibodydrug conjugates (ADCs) with […]
Significant progress made and well positioned for future growth 13 September 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces its unaudited interim results for the six months to 30 June 2023. Read more…
Ariceum develops satoreotide its first and best-in-class somatostatin receptor 2 antagonist in extensive stage small cell lung cancer Phase Ib study design will be presented at the European Association of Nuclear Medicine Congress 2023 (EANM 2023) in Vienna, Austria on 10th September 2023 Berlin, Germany, 7th September 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical […]
STORM’s lead programme is the first RNA methyltransferase inhibitor to enter clinical development. 9 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce that it will be presenting the […]
Pre-clinical data strongly supports progression of a METTL3 inhibitor in an immuno-oncology setting. STC-15 is the first molecule specifically targeting METTL3 to enter clinical development. 8 August 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and […]
